ATE206720T1 - Camphothecinderivate - Google Patents
CamphothecinderivateInfo
- Publication number
- ATE206720T1 ATE206720T1 AT96309470T AT96309470T ATE206720T1 AT E206720 T1 ATE206720 T1 AT E206720T1 AT 96309470 T AT96309470 T AT 96309470T AT 96309470 T AT96309470 T AT 96309470T AT E206720 T1 ATE206720 T1 AT E206720T1
- Authority
- AT
- Austria
- Prior art keywords
- alkylene
- groups
- camptothecin
- alkm
- chem
- Prior art date
Links
- 125000002947 alkylene group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- -1 camptothecin compound Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000004676 glycans Chemical group 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0018—Pullulan, i.e. (alpha-1,4)(alpha-1,6)-D-glucan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Developing Agents For Electrophotography (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34357595 | 1995-12-28 | ||
| JP20010596 | 1996-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE206720T1 true ATE206720T1 (de) | 2001-10-15 |
Family
ID=26511972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96309470T ATE206720T1 (de) | 1995-12-28 | 1996-12-23 | Camphothecinderivate |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US5892043A (de) |
| EP (1) | EP0781781B1 (de) |
| KR (1) | KR100352545B1 (de) |
| CN (2) | CN1073113C (de) |
| AT (1) | ATE206720T1 (de) |
| CA (1) | CA2192725C (de) |
| DE (1) | DE69615808T2 (de) |
| DK (1) | DK0781781T3 (de) |
| ES (1) | ES2164218T3 (de) |
| GR (1) | GR3037076T3 (de) |
| ID (1) | ID25979A (de) |
| MX (1) | MX9700222A (de) |
| PT (1) | PT781781E (de) |
| SG (2) | SG76585A1 (de) |
| TW (1) | TW473478B (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888988A (en) * | 1995-05-08 | 1999-03-30 | Chitogenics, Inc. | Covalently linked N,O-carboxymethylchitosan and uses thereof |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| WO1998014459A1 (de) * | 1996-09-30 | 1998-04-09 | Bayer Aktiengesellschaft | Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung) |
| DE19640207A1 (de) * | 1996-09-30 | 1998-04-02 | Bayer Ag | Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung) |
| SG88737A1 (en) | 1996-10-30 | 2002-05-21 | Tanabe Seiyaku Co | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof |
| ID23424A (id) * | 1997-05-14 | 2000-04-20 | Bayer Ag | Glikokonjugat dari 20(s)-kamptotesin |
| WO1999061061A1 (fr) * | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
| US6043367A (en) * | 1998-09-30 | 2000-03-28 | Roffler; Steve | Proactive antitumor compounds |
| US6509043B1 (en) * | 1998-11-25 | 2003-01-21 | Nutri Pharma Asa | Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
| US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6228855B1 (en) | 1999-08-03 | 2001-05-08 | The Stehlin Foundation For Cancer Research | Aromatic esters of camptothecins and methods to treat cancers |
| JP4776843B2 (ja) | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法 |
| MXPA02003719A (es) * | 1999-10-12 | 2002-08-30 | Cell Therapeutics Inc | Fabricacion de congujados de poliglutamato-agente terapeutico. |
| US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
| US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
| US20020077290A1 (en) * | 2000-03-17 | 2002-06-20 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
| TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| US20030092608A1 (en) * | 2001-08-21 | 2003-05-15 | Takayuki Kawaguchi | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| CN100393724C (zh) * | 2002-07-12 | 2008-06-11 | 中国医学科学院药物研究所 | 20-位酯化的喜树碱衍生物及其制法和其药物组合物与用途 |
| US20040204435A1 (en) * | 2003-04-09 | 2004-10-14 | Joachim Liehr | Alternating treatment with topoisomerase I and topoisomerase II inhibitors |
| ITRM20040240A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 7 con antagonisti delle integrine. |
| ES2361919T3 (es) * | 2004-09-07 | 2011-06-24 | Biocompatibles Uk Limited | Suministro de fármaco a partir de agentes embólicos. |
| ITPD20050242A1 (it) | 2005-08-03 | 2007-02-04 | Fidia Farmaceutici | Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico |
| FR2914305B1 (fr) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| FR2891149B1 (fr) * | 2005-09-26 | 2007-11-30 | Biodex Sarl | Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes. |
| FR2919188B1 (fr) * | 2007-07-27 | 2010-02-26 | Proteins & Peptides Man | Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (de) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| US12685781B2 (en) | 2014-04-10 | 2026-07-21 | Daiichi Sankyo Company, Limited | Anti-HER3 antibody-drug conjugate |
| US11185594B2 (en) | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| WO2018066626A1 (ja) | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療 |
| JPWO2018110515A1 (ja) | 2016-12-12 | 2019-10-24 | 第一三共株式会社 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| SG11201906554RA (en) | 2017-01-17 | 2019-08-27 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| US12667557B2 (en) | 2017-02-28 | 2026-06-30 | Daiichi Sankyo Company, Limited | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| EP3677589B1 (de) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Verbessertes verfahren zur herstellung eines antikörper-wirkstoff-konjugats |
| SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
| EP3794042B1 (de) | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Conjugue agent cytotoxique et anticorps anti-muc1-exatecan |
| EP3831853A4 (de) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | Protein-erkennende arzneimitteleinheit eines antikörper-wirkstoff-konjugats |
| IL325918A (en) | 2018-07-31 | 2026-03-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugates for use in the treatment of metastatic brain tumor |
| US12029736B2 (en) | 2020-02-25 | 2024-07-09 | Mediboston Limited | Camptothecin derivatives and conjugates thereof |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| US12521444B2 (en) | 2021-02-25 | 2026-01-13 | Fortvita Biologics Limited | Anti-HER2 antibody-drug conjugates and uses thereof |
| CN113952465A (zh) * | 2021-10-20 | 2022-01-21 | 中国药科大学 | 一种喜树碱前药及其制备方法和应用 |
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン，インコーポレイテッド | 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 |
| IL322897A (en) * | 2023-02-23 | 2025-10-01 | Phrontline Biopharma Hangzhou Co Ltd | Camptothecin derivatives and conjugates, methods for their preparation and medical uses |
| CN119371430A (zh) * | 2023-07-26 | 2025-01-28 | 上海医药集团股份有限公司 | 喜树碱类小分子及其抗体药物偶联物、制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0220601B1 (de) | 1985-10-21 | 1991-12-11 | Daiichi Seiyaku Co., Ltd. | Pyranoindolizinderivate und Verfahren zu ihrer Herstellung |
| US5180722A (en) | 1987-04-14 | 1993-01-19 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs |
| JP2540357B2 (ja) | 1987-06-24 | 1996-10-02 | 第一製薬株式会社 | 六環性化合物 |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| DK0540099T3 (da) | 1991-10-29 | 1996-06-17 | Glaxo Wellcome Inc | Vandopløselige camptothecinderivater |
| JPH06228141A (ja) | 1992-01-24 | 1994-08-16 | Takeda Chem Ind Ltd | 縮合複素環誘導体、その塩、その製造法および用途 |
| JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| JP2610792B2 (ja) * | 1993-02-26 | 1997-05-14 | 株式会社ディ・ディ・エス研究所 | 多糖誘導体および薬物担体 |
| GB9320781D0 (en) * | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
-
1996
- 1996-12-12 CA CA002192725A patent/CA2192725C/en not_active Expired - Fee Related
- 1996-12-19 ID IDP991154A patent/ID25979A/id unknown
- 1996-12-23 PT PT96309470T patent/PT781781E/pt unknown
- 1996-12-23 AT AT96309470T patent/ATE206720T1/de not_active IP Right Cessation
- 1996-12-23 TW TW085115910A patent/TW473478B/zh not_active IP Right Cessation
- 1996-12-23 DK DK96309470T patent/DK0781781T3/da active
- 1996-12-23 DE DE69615808T patent/DE69615808T2/de not_active Expired - Lifetime
- 1996-12-23 EP EP96309470A patent/EP0781781B1/de not_active Expired - Lifetime
- 1996-12-23 ES ES96309470T patent/ES2164218T3/es not_active Expired - Lifetime
- 1996-12-27 KR KR1019960073473A patent/KR100352545B1/ko not_active Expired - Fee Related
- 1996-12-27 US US08/773,182 patent/US5892043A/en not_active Expired - Fee Related
- 1996-12-28 SG SG1999000114A patent/SG76585A1/en unknown
- 1996-12-28 SG SG1996011938A patent/SG49994A1/en unknown
- 1996-12-30 CN CN96114098A patent/CN1073113C/zh not_active Expired - Fee Related
- 1996-12-30 CN CNB001335693A patent/CN1142935C/zh not_active Expired - Fee Related
-
1997
- 1997-01-07 MX MX9700222A patent/MX9700222A/es unknown
-
1999
- 1999-01-08 US US09/227,158 patent/US6512118B1/en not_active Expired - Fee Related
-
2000
- 2000-07-21 US US09/624,012 patent/US6617456B1/en not_active Expired - Fee Related
-
2001
- 2001-10-31 GR GR20010401948T patent/GR3037076T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0781781B1 (de) | 2001-10-10 |
| US6617456B1 (en) | 2003-09-09 |
| SG76585A1 (en) | 2000-11-21 |
| DE69615808T2 (de) | 2002-05-02 |
| ID25979A (id) | 1997-06-26 |
| DE69615808D1 (de) | 2001-11-15 |
| ES2164218T3 (es) | 2002-02-16 |
| CN1073113C (zh) | 2001-10-17 |
| CN1300733A (zh) | 2001-06-27 |
| DK0781781T3 (da) | 2001-11-26 |
| CA2192725A1 (en) | 1997-06-29 |
| PT781781E (pt) | 2002-03-28 |
| MX9700222A (es) | 1998-04-30 |
| EP0781781A2 (de) | 1997-07-02 |
| GR3037076T3 (en) | 2002-01-31 |
| US6512118B1 (en) | 2003-01-28 |
| EP0781781A3 (de) | 1998-04-01 |
| CN1142935C (zh) | 2004-03-24 |
| KR100352545B1 (ko) | 2003-01-24 |
| KR970042553A (ko) | 1997-07-24 |
| TW473478B (en) | 2002-01-21 |
| US5892043A (en) | 1999-04-06 |
| CA2192725C (en) | 2004-04-20 |
| CN1158334A (zh) | 1997-09-03 |
| SG49994A1 (en) | 1998-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0781781T3 (da) | Camptothecinderivater | |
| DK0757049T3 (da) | Camptothecinderivater | |
| TR200100438T2 (tr) | Hepatit C inhibitörü peptitler | |
| DE69604714D1 (de) | Stilbenderivate und diese enthaltende pharmazeutische Zusammensetzungen | |
| BG103945A (bg) | Производни на 4"-заместен-9-деоксо-9а-аза-9а- хомоеритромицин а | |
| DE69415445D1 (de) | Zytotoxische Stilben-Derivate und diese enthaltende pharmazeutische Zusammensetzungen | |
| IL136044A (en) | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same | |
| IL129238A0 (en) | N-(aryl/heteroarylacetyl) amino acid esters pharmaceutical compositions comprising same and methods for inhibiting b-amyloid peptide release and/ or its synthesis by use of such compounds | |
| DE69432644D1 (de) | Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum | |
| ES2120728T3 (es) | Inhibidores de la agregacion de plaquetas. | |
| DE69635996D1 (de) | Pharmazeutische zusammensetzungen mit hydroximsäurederivaten | |
| ATE142641T1 (de) | Neue peptid-verbindungen und verfahren zur herstellung davon | |
| KR910002899A (ko) | 혈조절 펩타이드 | |
| BR0309283A (pt) | Preparação lìquida compreendendo derivado de camptotecina e composição farmacêutica produzìvel por liofilização da preparação | |
| EP0376041A3 (de) | C63-Amidderivate von 34-de(acetylglucosaminyl)-34-deoxy-teicoplaninen | |
| BR9807506A (pt) | Derivados de amida e composições medicinais dos mesmos | |
| ES2052752T3 (es) | Derivados de aminoquinoleina antimalarica, procedimiento de preparacion y composicion farmaceutica que contiene los mismos. | |
| ATE255121T1 (de) | Antitumor-indolopyrolocarbazolderivat | |
| MX9603149A (es) | Derivados de camptotecina. | |
| ATE243219T1 (de) | 9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin | |
| DK0835265T3 (da) | Blodpladeaggregeringsinhibitorer indeholdende C-terminale aminosyrerester med aminerge sidekæder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |